Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew M Waters

Showing results (1-10 of 29) with videos related to

Pageof 3
Sort By:
Methods in Molecular Biology (Clifton, N.J.)|May 12, 2021
Validation of Isoform- and Mutation-Specific RAS AntibodiesAndrew M Waters, Channing J Der
Cold Spring Harbor Perspectives in Medicine|December 13, 2017
KRAS: The Critical Driver and Therapeutic Target for Pancreatic CancerAndrew M Waters, Channing J Der
Plos One|September 30, 2016
Single Synonymous Mutations in KRAS Cause Transformed Phenotypes in NIH3T3 CellsAndrew M Waters, Rachel Bagni, Franklin Portugal, et al.
Pediatric Blood & Cancer|February 21, 2025
RAS Pathway Mutations and Therapeutics in Vascular AnomaliesSara Alharbi, Svatava Merkle, Adrienne M Hammill, et al.
Frontiers in Oncology|May 27, 2024
Evaluation of KRAS inhibitor-directed therapies for pancreatic cancer treatmentSzu-Aun Long, Amber M Amparo, Grace Goodhart, et al.
Bioorganic & Medicinal Chemistry Letters|July 15, 2010
Synthesis and antiproliferative evaluation of 5-oxo and 5-thio derivatives of 1,4-diaryl tetrazolesAditya S Gundugola, Kusum Lata Chandra, Elisabeth M Perchellet, et al.
Anticancer Research|July 9, 2011
Bioactivity of synthetic 2-halo-3-aryl-4(3H)-quinazoliniminium halides in L1210 leukemia and SK-BR-3 mammary tumor cells in vitroJean-Pierre H Perchellet, Andrew M Waters, Elisabeth M Perchellet, et al.
Anticancer Research|November 17, 2012
Antitumor effects of synthetic 6,7-annulated-4-substituted indole compounds in L1210 leukemic cells in vitroJean-Pierre H Perchellet, Andrew M Waters, Elisabeth M Perchellet, et al.
Cancer Research|November 7, 2023
TEAD Inhibition Overcomes YAP1/TAZ-Driven Primary and Acquired Resistance to KRASG12C InhibitorsA Cole Edwards, Clint A Stalnecker, Alexis Jean Morales, et al.
Molecular Cancer Therapeutics|March 5, 2022
Concurrent Inhibition of ERK and Farnesyltransferase Suppresses the Growth of HRAS Mutant Head and Neck Squamous Cell CarcinomaSehrish Javaid, Antje Schaefer, Craig M Goodwin, et al.
Pageof 3

Showing results (1-10 of 29) with videos related to

Sort By:
Pageof 3
Methods in Molecular Biology (Clifton, N.J.)|May 12, 2021
Validation of Isoform- and Mutation-Specific RAS AntibodiesAndrew M Waters, Channing J Der
Cold Spring Harbor Perspectives in Medicine|December 13, 2017
KRAS: The Critical Driver and Therapeutic Target for Pancreatic CancerAndrew M Waters, Channing J Der
Plos One|September 30, 2016
Single Synonymous Mutations in KRAS Cause Transformed Phenotypes in NIH3T3 CellsAndrew M Waters, Rachel Bagni, Franklin Portugal, et al.
Pediatric Blood & Cancer|February 21, 2025
RAS Pathway Mutations and Therapeutics in Vascular AnomaliesSara Alharbi, Svatava Merkle, Adrienne M Hammill, et al.
Frontiers in Oncology|May 27, 2024
Evaluation of KRAS inhibitor-directed therapies for pancreatic cancer treatmentSzu-Aun Long, Amber M Amparo, Grace Goodhart, et al.
Bioorganic & Medicinal Chemistry Letters|July 15, 2010
Synthesis and antiproliferative evaluation of 5-oxo and 5-thio derivatives of 1,4-diaryl tetrazolesAditya S Gundugola, Kusum Lata Chandra, Elisabeth M Perchellet, et al.
Anticancer Research|July 9, 2011
Bioactivity of synthetic 2-halo-3-aryl-4(3H)-quinazoliniminium halides in L1210 leukemia and SK-BR-3 mammary tumor cells in vitroJean-Pierre H Perchellet, Andrew M Waters, Elisabeth M Perchellet, et al.
Anticancer Research|November 17, 2012
Antitumor effects of synthetic 6,7-annulated-4-substituted indole compounds in L1210 leukemic cells in vitroJean-Pierre H Perchellet, Andrew M Waters, Elisabeth M Perchellet, et al.
Cancer Research|November 7, 2023
TEAD Inhibition Overcomes YAP1/TAZ-Driven Primary and Acquired Resistance to KRASG12C InhibitorsA Cole Edwards, Clint A Stalnecker, Alexis Jean Morales, et al.
Molecular Cancer Therapeutics|March 5, 2022
Concurrent Inhibition of ERK and Farnesyltransferase Suppresses the Growth of HRAS Mutant Head and Neck Squamous Cell CarcinomaSehrish Javaid, Antje Schaefer, Craig M Goodwin, et al.
Pageof 3